Erratum

This article refers to:

RAS inhibitors’ dose-dependent efficacy: myth or reality?

Correction to: Taddei S. RAS inhibitors’ dose-dependent efficacy: myth or reality? Curr Med Res Opin. 2015 Jul;31(7): 1245-1256.

Following publication of this article, several errors have been discovered. These errors did not affect study conclusions.

Under the subheading, Effects on hard endpoints, the last paragraph should correctly read as follows:

“This difference between ACE inhibitors has been more recently confirmed in a large cohort study where hypertensive patients newly treated with lisinopril or perindopril were followed over a mean period of 5 years⁶⁰. Patients initiated with perindopril had an 8% reduction in all-cause mortality and a 15% reduction in cardiovascular mortality compared with those receiving lisinopril. In the meta-analysis of Savarese²⁶, only two ACE inhibitors showed a significant reduction of myocardial infarction with a broad range of benefit: perindopril (−27.6%) and ramipril (−19.3%) (figure 9). This relative 44% greater inhibition of myocardial infarction with perindopril compared to ramipril is consistent with a retrospective study in a large patient database in Taiwan⁶¹. Indeed, the per-protocol analysis showed that over the follow-up of 3.7 years, patients initiated with perindopril had a risk of all-cause mortality significantly lower than those receiving ramipril (−21%).”

Several errors arose in production involving the references:

Several citations were incorrectly tagged to text. This was caused by the removal of duplicate references without retagging. Reference 48 was a duplicate of reference 11; reference 41 was a duplicate of reference 32. The corrections are as follows:

Under the main heading Have all ACE inhibitors the same efficacy?:

• Second paragraph, reference 41 should be changed to reference 32 throughout.

Under the subheading BP reduction:

• First paragraph, reference 42 should be changed to 41; second paragraph, reference 43 should be changed to 42.

Under the subheading Vascular protection:

• First paragraph, first sentence, references 34,43–49 should be changed to 11,34,43–49.

• Second paragraph, first sentence, reference 52 should be changed to 49; last sentence, reference 44 should be changed to 43.

• Third paragraph, first sentence, reference 53 should be changed to 51.

• Fourth paragraph, first sentence, references 1,54,59 should be changed to 1,52,53.

• Fifth paragraph, first sentence, reference 44 should be changed to 43; and last sentence, reference 56 should be changed to reference 54.

• Sixth paragraph, first sentence, reference 45 should be changed to 44.

• Ninth paragraph, first sentence, reference 51 should be changed to 49; and reference 11 should be 19.

Under the subheading Effects on hard endpoints:

• First paragraph, reference 57 should be changed to 55; and reference 58 should be changed to 56.

• Second paragraph, second sentence, reference 59 should be changed to 57; reference 60 should be changed to 58; and refence 61 should be changed to 59.

• Third paragraph, first sentence, reference 62 should be changed to 60.

Figure legends:

• Figure 6, last sentence, reference 2 should be changed to 41.

• Figure 9, only sentence, reference 63 should be 26.

Table 2. Corrected citations are as follows:

• Peripheral endothelial function in hypertensive patients³⁴

• Coronary endothelial function in hypertensive patients⁴³

• Apoptosis in patients with coronary artery disease⁴⁴

• Endothelial progenitor cells in animal experimental models⁴⁵

• Remodeling in small arteries in hypertensive patients⁴⁶

• Carotid distensibility in hypertensive patients with type 2 diabetes¹¹

• Pulse wave velocity in hypertensive patients⁴⁷

• Pulse wave velocity and survival in patients with end-stage renal disease⁴⁸

• Atherosclerotic plaque in patients with coronary artery disease⁴⁹